



Interface Prescribing & New Therapies Subgroup



May 2013

Lubiprostone for Chronic Idiopathic Constipation

The Interface Prescribing and New Therapies Subgroup discussed the above at its meeting on the 21st May 2013. The recommendation of this subgroup is as follows:*

The Interface Prescribing & New Therapies Subgroup of the GMMMG considered the lubiprostone for chronic idiopathic constipation where modification of diet and other non pharmacological methods are inappropriate.

The group does not recommend the use of lubiprostone over other laxatives.

Current trial data shows efficacy against placebo but no comparative data are available making place in therapy difficult to determine. It may be useful in those patients who have tried at least two other laxatives for at least 6 months, in addition to lifestyle modification without achieving adequate relief.

The current price of Lubiprostone is £53.48 for one month's supply. This is much more expensive than other treatment options.

According to set criteria lubiprostone was deemed to be a low priority for funding.

Review date: May 2015

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.